Business news – Page 103

  • Business

    Business roundup: November 2011

    2011-10-26T15:15:00Z

    Interview: Gilles Cottier Source: © SAFC The SAFC boss wants to see fewer vendors in the market SAFC president Gilles Cottier wants SAFC to hit $1 billion (£644 million) in sales by 2015, an ambitious target given that the company made $650 million in sales in 2010. ...

  • IN-THE-PIPELINE_250
    Opinion

    Common sense and safety

    2011-09-29T13:41:00Z

    You have to make space for good sense when thinking about safety, argues Derek Lowe

  • Business

    Business roundup: October 2011

    2011-09-29T13:41:00Z

    Ireland still attractive to pharma industry Pharma and chemical products represent 50 per cent of Irish exports Less than a year has passed since internal economic turmoil in Ireland culminated in an unprecedented €83 billion (£71 billion) bailout, yet interest in pharma manufacturing in the country seems ...

  • PIPELINE_pg23_410
    Opinion

    'Pay for delay'

    2011-08-26T14:23:00Z

    Derek Lowe considers an increasingly popular business strategy in the drug industry, the much discussed 'pay for delay' deal

  • Business

    Business roundup: September 2011

    2011-08-26T11:29:00Z

    Challenges for the drugs to help you quit Source: © Shutterstock Tobacco kills six million people every year The share price of US-based Nabi Biopharmaceuticals has fallen by 70 per cent after it announced that its nicotine addiction treatment, NicVax, failed to reach its endpoint in the ...

  • OPINION-LOWE-250
    Opinion

    The pitfalls that prevent progress

    2011-07-28T15:17:00Z

    Derek Lowe highlights the less visible pitfalls on the road to a new drug

  • Business

    Business roundup: August 2011

    2011-07-28T14:10:00Z

    Companies making moves into Russia Several companies have made recent moves into Russia. Novartis has started building a new manufacturing site in St Petersburg. The site - to be completed by 2014 - will produce generic as well as branded drugs and create 350 jobs for local people. Novartis says ...

  • OPINION-LOWE-250
    Opinion

    The financial funfair

    2011-06-30T09:50:00Z

    The financial markets can be a rollercoaster ride, writes Derek Lowe, so should chemists working in industry worry about the company share price?

  • Business

    Business roundup: July 2011

    2011-06-30T09:43:00Z

    World digs deep for cheaper vaccination Source: © Ben Fisher/GAVI/2011 UK Prime M inister David Cameron talked of a ’vital issue’ World leaders have pledged $4.3 billion (£2.6 billion) over the next five years to vaccinate 250 million people in developing countries with the help of the ...

  • OPINION-LOWE-250
    Opinion

    Categorising chemists

    2011-05-31T11:23:00Z

    To the unfamiliar, chemists might all look the same. But some common categories are easy to identify, explains Derek Lowe

  • Business

    Business roundup: June 2011

    2011-05-31T10:12:00Z

    Succinic acid plans Dutch life and material sciences company DSM and French starch company Roquette Frères are together planning to build what they say will be the largest European plant for the production of succinic acid from biological sources. To be built on the Roquette site at Cassano Spinola ...

  • OPINION-LOWE-250
    Opinion

    Who counts as a chemist?

    2011-04-28T09:15:00Z

    The map of scientific disciplines is growing ever more complex. Derek Lowe surveys the country

  • Business

    Business roundup: May 2011

    2011-04-27T15:48:00Z

    Pharmaceutical US approval for AZ thyroid cancer drug The US Food and Drug Administration (FDA) has approved orphan drug vandetanib for the treatment of thyroid cancer. The drug candidate is owned by pharma major AstraZeneca. The approval refers to medullary thyroid cancer that cannot be removed by surgery or ...

  • OPINION-LOWE-200
    Opinion

    The return of the return of natural products

    2011-03-30T08:37:00Z

    'Natural products are back!' is a headline Derek Lowe has seen several times before

  • Business

    Business roundup: April 2011

    2011-03-29T15:02:00Z

    Pharmaceutical Forest pays $1.2bn for Clinical Data US pharma company Forest Laboratories has agreed to buy Clinical Data for $30 (£19) per share in cash, equivalent to $1.2 billion, plus $6 per share payable if Viibryd (vilazodone) reaches commercial milestones. Forest intends to use existing cash to finance the deal. ...

  • OPINION-LOWE-200
    Opinion

    The risk vs reward of drug discovery

    2011-02-24T10:48:00Z

    Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations

  • Business

    Business roundup: March 2011

    2011-02-24T10:32:00Z

    Venom kits for drug discovery research Drug discovery companies can now buy venom kits to help them find new avenues of investigation by high throughput screening. Each kit from Swiss company Bachem is a plate with a series of wells - each well contains peptide fragments from the venoms ...

  • OPINION-LOWE-200
    Opinion

    Elevating enzymes

    2011-01-31T09:55:00Z

    Enzymes have been giving chemists inferiority complexes since day one, says Derek Lowe. But there's no denying their potential

  • Business

    Business roundup: February 2011

    2011-01-31T08:59:00Z

    DuPont signs $6.3 billion Danisco deal Source: © Danisco Danisco divested its flavour and sugar businesses in the last five years US chemical major DuPont has agreed to buy Danish food ingredients and enzymes company Danisco for $5.8 billion (£3.7 billion), plus $500 million of Danisco ...

  • OPINION-LOWE-200
    Opinion

    Fluorine fanatics

    2011-01-05T09:59:00Z

    Some medicinal chemists can't get enough fluorines in their molecules. Derek Lowe explains the love-hate relationship